Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study

BACKGROUND: Immune checkpoint inhibitors (ICI) are anti-cancer drugs that act by enhancing anti-tumour immunity. Due to their mechanism of action, they have been associated with immune related adverse events (Ir-AE), including musculoskeletal manifestations. AIM: To assess a) the prevalence, clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Daoussis, Dimitrios, Melissaropoulos, Konstantinos, Dimitroulas, Theodoros, Andreadis, Haralambos, Christopoulou, Athina, Douganiotis, George, Makatsoris, Thomas, Koutras, Angelos, Georgiou, Panagiotis, Kalofonos, Haralabos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:
Research Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362123/
https://www.ncbi.nlm.nih.gov/pubmed/32676566
http://dx.doi.org/10.31138/mjr.31.2.239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362123/
https://www.ncbi.nlm.nih.gov/pubmed/32676566
http://dx.doi.org/10.31138/mjr.31.2.239

Ejemplares similares